Skip to main content

Advertisement

SpringerLink
Log in

Is mirabegron equally as effective when used as first- or second-line therapy in women with overactive bladder?

  • Original Article
  • Published:
International Urogynecology Journal Aims and scope Submit manuscript

Abstract

Introduction and hypothesis

No previous studies have investigated the efficacy of mirabegron 50 mg as the first-line therapy in OAB patients. Hence, the primary objective of this study was to evaluate the efficacy of mirabegron in treatment-naive patients in comparison with those who had discontinued antimuscarinic therapy because of insufficient efficacy.

Methods

All consecutive women who had pure OAB symptoms (including urgency with or without urgency incontinence and frequency) for at least 3 months were considered for this study. Women were divided into two groups: women without any previous pharmacological treatment for OAB (group 1) and women with a previous history of failed antimuscarinics therapy (group 2).

Results

At 3-month follow-up, the objective results on the basis of the frequency–volume chart showed a significant improvement in both groups. Furthermore, a significant reduction in the Overactive Bladder Questionnaire Short Form (OABq-SF) score and in the Indevus Urgency Severity Scale (IUSS) questionnaire were reported in both groups. However, the improvement in objective and subjective outcomes was superior in group 1 to that in group 2.

Conclusions

Mirabegron is efficacious in improving OAB symptoms in both naïve patients and those who discontinued primary antimuscarinic therapy; however, its efficacy is superior when prescribed as first-line therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21(1):5–26. doi:10.1007/s00192-009-0976-9.

    Article  PubMed  Google Scholar 

  2. Maggiore ULR, Salvatore S, Alessandri F, Remorgida V, Origoni M, Candiani M, et al. Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females. Expert Opin Drug Metab Toxicol. 2012;8(11):1387–408. doi:10.1517/17425255.2012.714365.

    Article  CAS  Google Scholar 

  3. Reynolds WS, McPheeters M, Blume J, Surawicz T, Worley K, Wang L, et al. Comparative effectiveness of anticholinergic therapy for overactive bladder in women: a systematic review and meta-analysis. Obstet Gynecol. 2015;125(6):1423–32. doi:10.1097/AOG.0000000000000851.

    Article  CAS  PubMed  Google Scholar 

  4. Maggiore ULR, Cardozo L, Ferrero S, Sileo F, Cola A, Torella M, et al. Mirabegron in the treatment of overactive bladder. Expert Opin Pharmacother. 2014;15(6):873–87. doi:10.1517/14656566.2014.898752.

    Article  CAS  Google Scholar 

  5. Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Drogendijk T, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296–305. doi:10.1016/j.eururo.2012.10.048.

    Article  CAS  PubMed  Google Scholar 

  6. Khullar V, Amarenco G, Angulo JC, Cambronero J, Hoye K, Milsom I, et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63(2):283–95. doi:10.1016/j.eururo.2012.10.016.

    Article  CAS  PubMed  Google Scholar 

  7. Thuroff JW, Abrams P, Andersson KE, Artibani W, Chapple CR, Drake MJ, et al. EAU guidelines on urinary incontinence. Eur Urol. 2011;59(3):387–400. doi:10.1016/j.eururo.2010.11.021.

    Article  PubMed  Google Scholar 

  8. National Institute for Health and Care Excellence (NICE). Mirabegron for treating symptoms of overactive bladder. National Institute for Health and Care Excellence: Clinical Guidelines. London: NICE; 2013.

  9. Herschorn S, Barkin J, Castro-Diaz D, Frankel JM, Espuna-Pons M, Gousse AE, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013;82(2):313–20. doi:10.1016/j.urology.2013.02.077.

    Article  PubMed  Google Scholar 

  10. Nitti VW, Khullar V, van Kerrebroeck P, Herschorn S, Cambronero J, Angulo JC, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract. 2013;67(7):619–32. doi:10.1111/ijcp.12194.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Rosa GM, Ferrero S, Nitti VW, Wagg A, Saleem T, Chapple CR. Cardiovascular safety of beta3-adrenoceptor Agonists for the treatment of patients with overactive bladder syndrome. Eur Urol. 2016;69(2):311–23. doi:10.1016/j.eururo.2015.09.007.

    Article  CAS  PubMed  Google Scholar 

  12. Uzun H, Zorba OU. Metabolic syndrome in female patients with overactive bladder. Urology. 2012;79(1):72–5. doi:10.1016/j.urology.2011.08.050.

    Article  PubMed  Google Scholar 

  13. Bunn F, Kirby M, Pinkney E, Cardozo L, Chapple C, Chester K, et al. Is there a link between overactive bladder and the metabolic syndrome in women? A systematic review of observational studies. Int J Clin Pract. 2015;69(2):199–217. doi:10.1111/ijcp.12518.

    Article  CAS  PubMed  Google Scholar 

  14. Hilt EE, McKinley K, Pearce MM, Rosenfeld AB, Zilliox MJ, Mueller ER, et al. Urine is not sterile: use of enhanced urine culture techniques to detect resident bacterial flora in the adult female bladder. J Clin Microbiol. 2014;52(3):871–6. doi:10.1128/JCM.02876-13.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Karstens L, Asquith M, Davin S, Stauffer P, Fair D, Gregory WT, et al. Does the urinary microbiome play a role in urgency urinary incontinence and its severity? Front Cell Infect Microbiol. 2016;6:78. doi:10.3389/fcimb.2016.00078.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Schneeweiss J, Koch M, Umek W. The human urinary microbiome and how it relates to urogynecology. Int Urogynecol J. 2016;27(9):1307–12. doi:10.1007/s00192-016-2944-5.

    Article  PubMed  Google Scholar 

  17. Leone Roberti Maggiore U, Salvatore S, Alessandri F, Remorgida V, Origoni M, Candiani M, et al. Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females. Expert Opin Drug Metab Toxicol. 2012;8(11):1387–408. doi:10.1517/17425255.2012.714365.

    Article  PubMed  Google Scholar 

  18. D’Agostino G, Maria Condino A, Calvi P. Involvement of beta3-adrenoceptors in the inhibitory control of cholinergic activity in human bladder: direct evidence by [(3)H]-acetylcholine release experiments in the isolated detrusor. Eur J Pharmacol. 2015;758:115–22. doi:10.1016/j.ejphar.2015.03.074.

    Article  PubMed  Google Scholar 

  19. Hsiao SM, Liao CH, Lin HH, Kuo HC. Duration of antimuscarinic administration for treatment of overactive bladder before which one can assess efficacy: an analysis of predictive factors. Int Neurourol J. 2015;19(3):171–7. doi:10.5213/inj.2015.19.3.171.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Korstanje C, Someya A, Hiroshi Y, Noguchi Y, Ukai M, Suzuki M, et al. Additive effects for increased bladder storage function with the antimuscarinic drug solifenacin and the selective b3-adrenoceptor agonist mirabegron in two rat models for in vivo bladder function. 43rd Meeting of the International Continence Society; Barcelona, Spain, 26–30 August 2013.

  21. Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol. 2015;67(3):577–88. doi:10.1016/j.eururo.2014.02.012.

    Article  CAS  PubMed  Google Scholar 

  22. Abrams P, Kelleher C, Staskin D, Kay R, Martan A, Mincik I, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World J Urol. 2016. doi:10.1007/s00345-016-1908-1.

    PubMed  Google Scholar 

  23. Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D, et al. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BESIDE). Eur Urol. 2016;70(1):136–45. doi:10.1016/j.eururo.2016.02.030.

    Article  CAS  PubMed  Google Scholar 

  24. MacDiarmid S, Al-Shukri S, Barkin J, Fianu-Jonasson A, Grise P, Herschorn S, et al. Mirabegron as add-on treatment to solifenacin in patients with incontinent overactive bladder and an inadequate response to solifenacin monotherapy. J Urol. 2016;196(3):809–18. doi:10.1016/j.juro.2016.03.174.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, University of Insubria, Varese, Italy

    Maurizio Serati, Paola Sorice, Simona Cantaluppi & Fabio Ghezzi

  2. Academic Unit of Obstetrics and Gynaecology, IRCCS AOU San Martino—IST, Largo R. Benzi 10, 16132, Genoa, Italy

    Umberto Leone Roberti Maggiore

  3. Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy

    Umberto Leone Roberti Maggiore

  4. Department of Experimental Medicine and Surgery, University Tor Vergata, Rome, Italy

    Enrico Finazzi Agrò

Authors
  1. Maurizio Serati
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Umberto Leone Roberti Maggiore
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paola Sorice
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Simona Cantaluppi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Enrico Finazzi Agrò
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fabio Ghezzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Publication Committee of the Italian Society of Urodynamics

Corresponding author

Correspondence to Umberto Leone Roberti Maggiore.

Ethics declarations

Financial disclaimers/conflicts of interest

None.

Funding

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Serati, M., Leone Roberti Maggiore, U., Sorice, P. et al. Is mirabegron equally as effective when used as first- or second-line therapy in women with overactive bladder?. Int Urogynecol J 28, 1033–1039 (2017). https://doi.org/10.1007/s00192-016-3219-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00192-016-3219-x

Keywords

Search

Navigation